Pluristem Therapeutics (PSTI) Receives Key Placental Cell Therapy Patent in Australia
1/8/2014 9:19:16 AM
HAIFA, Israel, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent in Australia. Patent #2008300185, titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced thereby for Therapy," covers the use of adherent placental cells for the treatment of ischemia, which is a restriction of blood supply to tissues, and for treatments of conditions requiring connective tissue repair or regeneration.
Help employers find you! Check out all the jobs and post your resume.
comments powered by